Table 1 Baseline demographic and clinical characteristics of PLWH in care at sites across the United States overall and by anemia statusa
Participant characteristics | All participants (N = 15,126) | Developed anemia during follow-up (n = 1086) | Developed severe anemia during follow-up (n = 465) |
|---|---|---|---|
Age (median, IQR) | 44 (35–51) | 46 (39–53) | 46 (39–53) |
Female | 2620 (17) | 303 (28) | 156 (34) |
Race/ethnicity | |||
 White | 6712 (44) | 411 (38) | 148 (32) |
 Black | 5560 (37) | 529 (49) | 243 (52) |
 Hispanic | 2145 (14) | 108 (10) | 56 (12) |
 Other/missing | 709 (5) | 38 (3) | 18 (4) |
Years in CNICS at baseline (median, IQR) | 1.1 (0.5–6.0) | 2.2 (0.5–7.0) | 3.0 (0.5–7.7) |
Viral load ≥400 copies/ml | 3314 (22) | 338 (31) | 170 (37) |
CD4 count (cells/mm3) | |||
  < 100 | 777 (5) | 107 (10) | 78 (17) |
 100–199 | 1236 (8) | 99 (9) | 64 (14) |
 200–349 | 2686 (18) | 219 (20) | 122 (26) |
 350–499 | 3323 (22) | 233 (22) | 79 (17) |
  ≥ 500 | 7104 (47) | 428 (39) | 122 (26) |
Hepatitis C virus coinfection | 2556 (17) | 321 (30) | 146 (31) |
Kidney function (eGFR) | |||
  < 30 | 164 (1) | 25 (2) | 23 (5) |
 30–59 | 620 (4) | 51 (5) | 34 (7) |
  ≥ 60 | 14,342 (95) | 1010 (93) | 408 (88) |
BMI (kg/m2) | |||
  < 18.5 | 352 (2) | 24 (2) | 20 (4) |
 18.5 to < 25.0 | 6494 (43) | 472 (44) | 207 (44) |
 25.0 to < 30.0 | 5199 (34) | 339 (31) | 128 (28) |
  ≥ 30.0 | 3081 (21) | 251 (23) | 110 (24) |
ART use | 12,070 (80) | 821 (76) | 351 (75) |
MCV (fL) | 91 (87–95) | 91 (86–96) | 90 (85–96) |
Smoking status | |||
 Never | 6211 (41) | 408 (38) | 188 (41) |
 Former | 3492 (23) | 195 (18) | 80 (17) |
 Current | 5423 (36) | 483 (44) | 197 (42) |
Hazardous alcohol useb | 4239 (28) | 244 (22) | 110 (24) |
Illicit drug usec | 2283 (15) | 165 (15) | 64 (14) |